Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-06-19, Stock:NVS, The news for the past five days is as follows:
2019-06-12: NEWS1: Roche's Rituxan Gets Priority Review for Blood Disorder.NEWS2: Novartis Reports Data on Cosentyx for Psoriatic Arthritis.
2019-06-13: NEWS1: Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris.NEWS2: Top Analyst Reports for Visa, Netflix & Accenture.NEWS3: Top Analyst Reports for Visa, Netflix & Accenture.NEWS4: Top Analyst Reports for Visa, Netflix & Accenture.NEWS5: Ligand Inks Oncology Drug Discovery Deal With PhoreMost.NEWS6: Ligand Inks Oncology Drug Discovery Deal With PhoreMost.NEWS7: Ligand Inks Oncology Drug Discovery Deal With PhoreMost.NEWS8: A Stock Fund Challenges the Definition of Growth. It’s Paying Off..NEWS9: Novartis Reports Data on Cosentyx for Psoriatic Arthritis.NEWS10: Novartis Reports Data on Cosentyx for Psoriatic Arthritis.NEWS11: Roche's Rituxan Gets Priority Review for Blood Disorder.NEWS12: Roche's Rituxan Gets Priority Review for Blood Disorder.
2019-06-14: NEWS1: Bluebird Bio prices gene therapy at nearly $1.8m.NEWS2: Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris.NEWS3: Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris.
2019-06-17: NEWS1: J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study.NEWS2: J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study.NEWS3: Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz.NEWS4: Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz.NEWS5: J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study.NEWS6: Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz.
2019-06-18: NEWS1: Online pharmacy flags possible new impurity in blood pressure drug.NEWS2: Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status.NEWS3: Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status.NEWS4: Roche's Rozlytrek Gets Approval in Japan for Solid Tumors.NEWS5: Roche's Rozlytrek Gets Approval in Japan for Solid Tumors.NEWS6: Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status.NEWS7: Alcon Inc. -- Moody's assigns Baa2 ratings to Alcon Inc.'s unsecured debt facilities.NEWS8: Roche's Rozlytrek Gets Approval in Japan for Solid Tumors.

Answer: Rise